Pharmacolog introduces ReVal ™ at EAHP in Gothenburg

At the European Conference EAHP, which takes place in Göteborg 21-23 March, Pharmacolog will introduce ReVal ™. ReVal ™ is a system to facilitate the reconstitution of medication in pediatric care. The system is based on the prototype developed with Astrid Lindgren’s children’s hospital with contributions from Vinnova.

At the annual conference of the European Association of Hospital Pharmacists (EAHP), Pharmacolog will for the first time show ReVal™. ReVal™ is a system that facilitates nursing staff in pediatric care to prepare drugs. The system uses validated instructions stored in the ePed national database and offers appropriate methods for quality assurance of the prepared drug prior to being given to the patient. DrugLog® control is used for the most critical drugs while barcode scanning, or double control is used for less sensitive substances or non-intravenous drugs. The system provides an improved work process and facilitates healthcare professionals in complex and critical drug preparations.

ReVal™ is still under development, but Pharmacolog aims to be able to launch the product in the Nordic region during the fall. The system can link to other databases than the Swedish ePed and will be launched internationally within shortly.

Mats Högberg, CEO of Pharmacolog, comments: “We are very pleased to present ReVal™ at EAHP. It is particularly important to develop systems that make it easier for health care institutions to handle medication in pediatric care. ReVal™ is also a good example of how to integrate our DrugLog® into a system that greatly simplifies workflow. Initially, the system is working against the Swedish ePed database but is prepared to be able to handle other data sources. There are several similar international initiatives and there is a great interest in solutions that combines validated instructions with quality control methods in an efficient workflow. We therefore see good opportunities for an international launch very soon. “

Kommuniké från extra bolagsstämma i Pharmacolog den 25 april 2018

Aktieägarna i Pharmacolog i Uppsala AB (publ) höll extra bolagsstämma den 25 april 2018 i Uppsala och beslutade om följande:

Ny bolagsordning

Stämman beslutade att anta en ny bolagsordning enligt vilken § 5 erhåller följande lydelse:

5: Antalet aktier skall vara lägst 3 750 000 och högst 15 000 000 stycken.

Därutöver görs mindre korrekturjusteringar i § 8 och § 10.

Sammanläggning av B-aktier

Stämman beslutade att minska antalet aktier i bolaget genom att två (2) aktier av serie B sammanläggs till en (1) aktie av serie B.

Styrelsen bemyndigades att fastställa avstämningsdagen för sammanläggningen, dock att avstämningsdagen inte får bestämmas så att den infalle...

Pharmacolog is granted patent in the United States

Pressrelease in Swedish

Pharmacolog has been granted a patent in the United States regarding method and technique for adaptive dosage during intravenous drug treatments. In May 2016, the company received a positive review report on its PCT application and then applied for patents in the US, China and Europe.

The granted patent relates to method and technique for so-called adaptive dosage associated with intravenous treatments in health care, where careful dosage over time is crucial for successful patient recovery. For example, during treatment with chemotherapy or intravenous antibiotics. Today, there are no opportunities for such individualized dose regulation. The patent opens for a new...

Kallelse till extra bolagsstämma

Aktieägarna i Pharmacolog i Uppsala AB (publ), org.nr 556723-6418 (”Bolaget”), kallas härmed till extra bolagsstämma onsdagen den 25 april 2018 kl. 16:00 i Advokatfirman Lindahls lokaler på Vaksalagatan 10, Uppsala.

Anmälan m.m.

Aktieägare som önskar delta vid bolagsstämman skall:

dels vara införd i den av Euroclear Sweden AB förda aktieboken torsdagen den 19 april 2018, och dels anmäla sin avsikt att närvara senast fredagen den 20 april 2018 per post på adress Pharmacolog i Uppsala AB (publ), Ekeby Bruk A9, 752 75 Uppsala, eller per e-post till mats.hogberg@pharmacolog.se.

Vid anmälan bör uppges aktieägarens namn, person- eller organisationsnummer (eller motsvarande), aktieinnehav, adre...

DrugLog evaluation in New York completed

The evaluation carried out at two hospitals in New York has now been completed with very good results. The evaluation lasted two months in the framework of a so-called Drug Diversion program. The hospital will during the summer initiate a formal procurement process of equipment.

Late in 2017, the Company signed an agreement with a reputable hospital chain in New York to evaluate DrugLog for Drug Diversion at two of the organization’s hospitals. The evaluation conducted by the hospital has shown that DrugLog can very well be used to control drug-based intravenous drugs within the framework of a Drug Diversion program. Drug Diversion means that the hospital controls that narcotic drugs used d...